SoloHealth to expand health-and-wellness kiosk to 4,000 locations by 2014
ATLANTA, Ga. — SoloHealth on Thursday announced it has plans in place to expand its FDA-approved SoloHealth Station health-and-wellness digital kiosks to more than 2,500 store locations by mid-2013, scaling to more than 4,000 by 2014.
“We are fundamentally changing consumer healthcare access and along with way providing advertisers with a completely unique and effective way to reach consumers in a direct, highly personalized and engaging manner,” stated Bart Foster, SoloHealth CEO. “Our platform allows brands to become solutions for consumers — reaching health-conscious shoppers when they are engaged and interested in products that are aisles away, not miles away.”
The SoloHealth Station provides health screenings for vision, blood pressure, weight and body mass index, a symptom checker as well as an overall health assessment free of charge. SoloHealth also helps connect consumers to local professionals through their databases, helping people enter the most appropriate and accurate point in the healthcare system. A cloud-based platform, the SoloHealth Station is backed by technology that allows for flexibility to make changes remotely and quickly so the company can continue to expand the services offered.
The SoloHealth Station also offers highly personalized, targeted and interactive opportunities for consumers, advertisers and retailers by placing kiosks in high-traffic retail locations and offering online advertising — including interactive banners, 15- to 30-second interstitial videos, e-newsletters, email activation and digital signage. Advertisers can engage shoppers through interactive displays, video and custom solutions that can be tailored to specific advertising needs.
According to data supplied by SoloHealth, consumers are twice as likely to engage in nontargeted media than average online consumers; four times more likely when reached through relevant content; and six times more likely to engage when targeting is based on consumers’ answers to health-related questions.
Sanofi Pasteur seeks to expand seasonal flu protection from three influenza strains to four
SWIFTWATER, Pa. — Sanofi Pasteur on Thursday announced it has filed for approval of a four-strain flu shot to the Food and Drug Administration. An action date is anticipated in the second quarter of 2013.
"The addition of a fourth influenza virus strain to the seasonal influenza vaccine formulation has the potential to make a substantial impact in reducing influenza disease and influenza-related complications, hospitalizations and deaths among those who contract the disease," stated David Greenberg, senior director, U.S. scientific and medical affairs, Sanofi Pasteur. "Two influenza B-lineage strains typically co-circulate in the U.S each year, so it makes sense to include both in the vaccine rather than attempting to predict which of the two will be the dominant strain. In fact, in six of the past 12 influenza seasons, the B strain selected by health authorities for inclusion in the vaccine was not the predominant B-lineage strain that circulated during the next influenza season."
The strains for each season’s influenza vaccine are selected by the FDA, in consultation with global health authorities, from the strains anticipated to circulate in the approaching influenza season. Seasonal influenza vaccines contained only two strains (one strain of type A influenza and one strain of type B influenza) until 1978, when the decision was made to incorporate a second type A influenza strain in order to provide protection against the two different A strains that were co-circulating. From then until now, influenza vaccines have been trivalent to help protect against three strains of influenza virus (two of type A and one of type B).
However, since the influenza B Victoria lineage re-emerged worldwide in 2001-2002, two influenza B strains (one each from the Victoria and Yamagata lineages) have co-circulated with varying prevalence, making it difficult to predict the next season’s dominant B strain. Even in years when the correct B virus strain was selected for the vaccine, some influenza disease was caused by the B strain omitted from the vaccine. These factors raised the hypothesis that the addition of a second B-lineage strain to expand the licensed trivalent influenza vaccine to a quadrivalent vaccine could help reduce flu incidence.
Ansell Healthcare takes LifeStyles thin condoms thinner with Zero launch
ISELIN, N.J. — Ansell Healthcare on Wednesday announced the launch of Zero and Zero Larger. Zero is the thinnest latex condom now offered in America, 45% thinner than Ansell’s standard latex design, and Zero Larger is now the thinnest large condom in the market in the United States, the company stated.
According to consumer focus groups, condom users are consistently searching for more sensitive and better-fitting designs, and are willing to try different brands and styles to discover the condoms that best suit their needs.
"At Ansell, we are constantly striving to bring sexually active consumers the most advanced products on the market, developed by conducting rigorous consumer research," stated Carol Carrozza, VP sales and marketing North America for Ansell Healthcare. "Responding to consumer requests, we are thrilled to introduce our thinnest condoms yet, Zero and Zero Larger, offering users what they desire most: greater sensitivity, extended pleasure and quite frankly, better sex."
The release of Zero also features an innovation in packaging design for the condom category. The unique packaging features a contemporary, matchbox-like design that slides open for easy access. The product name, metallic Zero logo, solid white background and packaging fonts all demonstrate a modern, sleek and sexy update to typical condom packaging — a new, innovative look for the new, advanced Zero series.